Rheumatoid arthritis: common questions

What the research found.

• Anti-CCP has a pooled sensitivity of 67 percent, so about a third of people with rheumatoid arthritis test negative. In early disease the cohort studies put that sensitivity lower still, at 54 percent. So a negative result is common enough in people who have the disease that it settles very little on its own.

  Whiting and colleagues, Annals of Internal Medicine, 2010

• CRP was under 10 mg/L at first measurement in 44 percent of one rheumatoid arthritis cohort and 58 percent of another. All three of ESR, CRP, and rheumatoid factor were normal in about 15 percent of those patients. Only about a quarter of them had all three abnormal at once.

  Sokka and Pincus, Journal of Rheumatology, 2009

• Treating to a composite target raised remission rates substantially across the strategy trials. The TICORA trial reported 65 percent against 16 percent on conventional care, and FIN-RACo reported 37 percent against 18 percent. Those were drug strategies rather than lifestyle programs, which is what makes the comparison a fair one to quote here.

  Hock and colleagues, SN Comprehensive Clinical Medicine, 2021

• Resistance exercise reduced disease activity in rheumatoid arthritis with a standardized mean difference of 0.69 on the DAS28, a score built from a 28-joint count, a blood marker, and a health rating, which was the strongest modality in that analysis. It's a genuine effect on the very measure treatment moves. It arrives at that effect on a different scale from what the strategy trials achieved, which is why the two belong together.

  Wen and Chai, Medicine, 2021

• Affective distress in rheumatoid arthritis was associated with lower rates of DAS28 remission, at an odds ratio of 1.77. It was associated with greater disability at an odds ratio of 7.37 and higher mortality at a hazard ratio of 2.98. Those are observational associations rather than demonstrations of cause.

  Sweeney and colleagues, Rheumatology International, 2024

Where the misunderstandings cluster

Almost every question people bring to this disease falls into one of two groups, and they pull in opposite directions. The first group assumes the blood tests settle things, so a normal result means no disease and a raised one means active disease. The second assumes that because rheumatoid arthritis responds to lifestyle in measurable ways, lifestyle might be enough.

Both are wrong in ways that cost people something real. Believing normal tests rule the diagnosis out delays treatment, and the strategy trials show what early intensive treatment is worth. Believing diet and exercise can replace treatment produces the same delay by a different route.

The answers below give you their figures so you can see the size of what's being claimed. Where a question has no good answer, the answer on this page says so rather than filling the space with something plausible. That happens more often here than anyone would like.

What the blood tests can and can't settle

The single most useful fact about testing in rheumatoid arthritis is how often the tests are normal in people who have it. Anti-CCP has a pooled sensitivity of 67 percent, so about a third of people with the disease test negative, and in early disease the cohort studies put it at 54 percent. CRP was under 10 mg/L at the first recorded measurement in 44 percent of one cohort and 58 percent of another.

All three of ESR, CRP, and rheumatoid factor were normal in about 15 percent of people with the disease in those cohorts, and only about a quarter had all three abnormal. That's the opposite of the impression most people bring into a clinic. It's the reason a swollen joint on examination counts for more than a reassuring number.

The tests earn their place on the positive side. Anti-CCP is specific in 95 to 96 percent of cases, so a positive result in someone with swollen small joints is strong evidence. Diagnosis rests on the picture of joints, the length of morning stiffness, and the examination, with the antibodies supporting that rather than replacing it.

What treatment achieves, and what lifestyle adds

Treating to a target rather than to clinical impression is among the better-established ideas in rheumatology. Trials of protocolised treatment to a composite score consistently beat conventional care on remission, with TICORA reporting 65 percent against 16 percent, CAMERA 50 against 37, a DAS28-driven strategy 38 against 21, and FIN-RACo 37 against 18. The DAS28 behind that strategy is a single score built from a 28-joint count, a blood marker, and your own health rating. That's the scale treatment operates at.

Exercise produces a real effect on the same measure at a different scale. Resistance exercise reduced DAS28 with a standardized mean difference of 0.69, the strongest modality in that analysis, and a network analysis found Pilates best for pain, combined exercise best for stiffness, and tai chi best for DAS28. Those effects are worth having and they're worth having alongside treatment.

The trial people most want has never been run, which is a structured lifestyle program compared directly against a disease-modifying drug. Until somebody does, anyone telling you diet and exercise can replace your medication is extrapolating rather than reporting. That's worth knowing before you decide.

The supplements that move markers and not disease

Two supplements are taken by a great many people with this diagnosis and both have been studied carefully enough to say something definite. Omega-3 supplementation reliably lowers the omega-6 to omega-3 ratio, raises EPA and DHA, and reduces triglycerides, all at P values below 0.001. In the same trials, ESR, CRP, and DAS28 were slightly reduced without reaching statistical significance.

Vitamin D produces a similar pattern, and it has been studied just as carefully. People with rheumatoid arthritis have lower levels than controls, by 16.52 nmol/L, and the correlation with disease activity is negligible at negative 0.13. Supplementation raised serum vitamin D and improved pain scores and CRP significantly, and left DAS28 statistically unchanged at a standardized mean difference of 0.09.

The picture in both cases is a marker moving without the disease following. That isn't a reason to stop something that helps your pain, and it is a reason to know what you're buying. Marine oil did reduce pain across 22 trials at a standardized mean difference of 0.21, with an upper confidence limit that barely clears no effect, and function was unchanged.

Sleep and mood, which aren't side issues here

Sleep problems affect the majority of people with this disease. Pooled prevalence was 60.9 percent, with insomnia symptoms at 58 percent, sleep apnea measures at 65 percent, and poor subjective sleep quality at 61 percent. Depression, pain, fatigue, female sex, and older age were all associated with it.

Mood is associated with hard outcomes in ways that most people find surprising. Affective distress was associated with lower DAS28 remission at an odds ratio of 1.77, greater disability at an odds ratio of 7.37, and higher mortality at a hazard ratio of 2.98, that last from four studies with substantial heterogeneity. Those are observational associations rather than demonstrations of cause.

What complicates the picture is that treating the mood hasn't produced matching effects on the disease. Mindfulness-based interventions pooled at negative 0.44 on DAS28-CRP and negative 0.58 on pain, neither statistically significant. Cognitive behavioral therapy for insomnia missed its polysomnography primary outcome at a P value of 0.068, while improving the Insomnia Severity Index by 9.85 points at 26 weeks. The associations are strong, the treatment effects on disease activity aren't, and both of those belong in the same sentence.

Common misconceptions.

Questions patients ask.